antioxidant protocols, or of giving alpha-tocopherol rather than mixed tocopherols (eg, alpha-tocopherol alone can drive down levels of gamma-tocopherol, another crucial antioxidant), naturally, were not widely acknowledged.
antioxidant protocols, or of giving alpha-tocopherol rather than mixed tocopherols (eg, alpha-tocopherol alone can drive down levels of gamma-tocopherol, another crucial antioxidant), naturally, were not widely acknowledged.
Within the last several months, though, a new twist has emerged on this study-one that has received little publicity, although our corresponding editor, Dr. Ralph Moss, did cover it in his newsletter at cancerdecisions.com. 4 Further analysis of Bairati's study population showed that the excess recurrences were restricted to those patients who received supplements and continued to smoke throughout radiation therapy. 5 Specifically, among smokers, the hazard ratio (HR) for recurrences was 2.41; the hazard ratio was 3.38 for cancer-specific mortality. All cause mortality was also increased (HR 2.26). For nonsmokers who received supplements, the hazard ratios were all around one, that is, there was no excess risk of mortality compared to those in the placebo group. This pattern was true of both those who received beta-carotene and those who received alphatocopherol alone. Those who smoked before radiation therapy but stopped during therapy, and those who quit during but resumed after the end of therapy had no excess risk of mortality. This is an important realization for clinicians. It implies that the benefits of antioxidant supplementation for reducing side effects are available for patients who do not smoke, or who quit smoking during therapy. Since many head and neck cancer patients are, in fact, smokers, it also provides some specific motivation to stop smoking at least for the time of therapy, even if they're not able to stop in the long term.
Another reanalysis of Bairati's study, actually published before the study just discussed, provides a different perspective on the role of beta-carotene during radiation. In this study, the authors reported on dietary intakes of betacarotene and alpha-tocopherol in the entire supplementation study group. 6 Food frequency questionnaire data and plasma levels of beta-carotene and alpha-tocopherol were compared to data on acute adverse effects of radiation therapy and local recurrences. Those patients with the highest dietary beta-carotene had significantly fewer radiation side effects (odds ratio of 0.61, a near 40% reduction in side effects). There was a similar tendency for plasma beta-carotene and side effects (odds ratio of 0.73). Those with the highest plasma levels of beta-carotene also had a 33% reduction in local recurrences (odds ratio of 0.67). Alpha-tocopherol was not related to either side effects or I n 2005 and again in 2006, the oncology community turned its attention to questions surrounding antioxidant use in cancer when Isabella Bairati and colleagues published results of a trial of antioxidant use during radiation therapy. The trial was designed to investigate whether supplemental (synthetic) beta-carotene and alpha-tocopherol would reduce the incidence of second primary cancers as well as improve cancer-free survival in head and neck cancer patients treated with radiotherapy. The results of two large trials of betacarotene were published during the early part of the study, showing that beta-carotene had no helpful effect on cancer prevention, and in fact increased lung cancer in smokers. Beta-carotene was then dropped from Bairati's intervention trial after about a fifth of the study's patients had been recruited. Because previous epidemiological studies had indicated that antioxidants might both improve side effect profiles and retard recurrences, it was expected that the remaining alpha-tocopherol supplement would result in better outcomes for the intervention group. Unfortunately, the results indicated higher rates of second primary cancers in the supplemented group, along with more recurrences during supplementation, higher all-cause mortality, and a trend towards higher cancerspecific mortality. 1,2 As many integrative practitioners observed, though, side effects in particular organs were less in the group that received beta-carotene and alphatocopherol (though not alpha-tocopherol alone).
What followed was an outburst of publicity on the dangers of antioxidants-a media phenomenon that has peppered the clinical landscape regularly for the past several years. Oncology Times, for instance, ran a story about the study in its October 2005 issue, headlining both the reduction of side effects and the increase in recurrences. 3 The study entered the lore of the many oncologists who warn cancer patients not to take antioxidants-unsurprisingly, since Bairati's findings are certainly concerning. The concerns of integrative practitioners about giving high doses of single antioxidants, rather than comprehensive cancer recurrence. This is a surprisingly vivid demonstration of the potential impacts of diets high in carotenoidcontaining foods (ie, fruits and vegetables) in improving both tolerance and results of therapy. Again, it provides the clinician with specific data to counsel patients on dietary intakes during radiation therapy.
Both of these new studies put the antioxidant-radiation therapy debate in an entirely new light. It's not surprising that Bairati's study used the isolated phytochemical forms of beta-carotene and alpha-tocopherol as supplements during their study, which began in 1994, as our understanding of phytochemicals was just starting out. But the synthetic, simple, isolated carotenoid was soon shown to compromise smokers by manifesting a prooxidant state in the abnormal internal milieu created by tobacco. It is perhaps this prooxidant potential of the concentrated antioxidant supplement that created all the trouble for beta carotene-consuming smokers during therapy, rather than the antioxidant nature of the supplement. When the antioxidant was allowed to do its work without the ill effects of tobacco, its ability to reduce side effects without affecting therapeutic efficacy was shown. Similarly, when beta-carotene was consumed in its natural state, in the context of the mixed carotenoids in foods, its helpful nature was again manifested. The picture that has been in the mind of the oncology community, in which antioxidants created a "shield" that protected tumors from the effects of radiation, does not apply here. Rather, it was a supplement that is known to shift to a prooxidant state in smokers that was associated with higher rates of mortality, recurrence, and second primaries. A general antioxidizing environment, without tobacco mischief and with the support of a good diet, paradoxically seems to help, rather than hinder, the strong oxidizing action of radiation.
I can't claim to be a true adherent of "science by press release," but there is something to be said for the ability of the popular press to bring articles to the attention of patients and practitioners in a world in which we're overwhelmed by information. In the case of the two new analyses of the Bairati data, though, Dr. Moss seems to be the only person who is trying to get this news out. The popular press today seems to be in a mood to pick up on studies that "debunk" complementary and alternative medicine, and has ignored this clinically critical renovation in the antioxidant-radiation therapy data. Bringing these articles to the attention of Integrative Cancer Therapies readers is our way of doing the best that we can to counteract the current adverse press environment.
On the other hand, I'm not entirely averse to press releases, and readers may have seen press releases about this very issue of Integrative Cancer Therapies. We are carrying an article by György Horvath on canine detection of ovarian cancer using its specific odor. A previous Integrative Cancer Therapies article 7 on canine detection of cancer odorspopularly termed "sniffer dogs" and cancer-wound up being an object of press attention around the globe and throughout the Internet, and has reportedly become a legend in the offices of our publisher, Sage Publications. Horvath and colleagues are advancing this field by exploring the possible endogenous odors of cancers that would not be detectable to dogs as inflammation or necrosis. While there is not a high likelihood that dogs will be hanging out in your neighborhood cancer clinic and sniffing people to diagnose their cancers, there is the very real possibility that early malignant tissue could be detected, ultimately, by gas chromatograph paradigms growing out of this basic research on molecular aspects of cancer. Nonetheless, our close relationship with the canine members of our families makes their contribution to this basic research compelling reading everywhere.
Other exciting articles are also in this issue. Susan Bauer-Wu, now of Emory University, and her colleagues have contributed a pilot study of using mindfulness meditation for patients receiving hematopoietic stem cell transplantation. This study provides an example of how integrative techniques can be used to help patients in one of our most difficult treatments with the serious levels of distress it causes. We look forward to seeing further work and studies by Dr. Bauer-Wu and her colleagues. Richard Lee, of the University of Chicago, has contributed a preliminary survey on the opinions of Chinese and US oncologists on the use of complementary and alternative (CAM) therapies with cancer patients. This work demonstrated surprising areas of affirmation of the CAM therapies. Differences in the approaches of the Chinese and US physicians were also intriguing.
We also have two review articles in the issue. Ira Cantor has contributed a review on vitamin D and its relation to cancer. Vitamin D, which has been called the "supplement of the decade," is becoming of increasing interest for its potential anticancer applications, and Dr. Cantor provides an interesting integrative assessment of its use, as well as reviewing relevant literature. Additionally, a review on tumor-associated macrophages and their relationship to cancer was contributed by Guruvayoorappan Chandrasekharan, from India.
Anthroposophical medicine is considered by many Canadian and European practitioners to be an important CAM approach to cancer. In addition to the use of mistletoe as an anticancer agent, this approach uses philosophical and psychological therapies for cancer patients. It makes its first appearance in the journal in a review article and case series from Walter Legnani, an Italian oncologist who uses comprehensive anthroposophical therapy with his patients.
One of our areas of interest is in the development of innovative therapeutic techniques, and in this issue we present an article by Xiaohuai Wang and colleagues on a nascent experimental approach, sonodynamic therapy. Sonodynamic therapy works in somewhat the same way as photodynamic therapies. A sonosensitizing chemical is given to an experimental animal, which brings about a localized sensitivity to sound waves in tumor tissue. Ultrasound is then applied, resulting in cytotoxicity for the tumor cells, but leaving normal cells intact. A comprehensive in vivo assessment of a new sonosensitizing compound is presented in Wang's paper. It will be interesting to see if a new therapeutic approach can be developed from this work.
Finally, the Integrative Tumor Board feature reappears in this issue, with a pancreatic cancer case. Leslie Meng, a medical oncologist, summarizes the conventional approach to this case. Lise Altschuler and Dan Rubin, an associate editor of Integrative Cancer Therapies, provide a naturopathic approach. A physical therapist from the Block Center for Integrative Cancer Treatment, Sarah Kranz, has contributed the first physical care assessment that we have featured in the Tumor Board. Finally, Gilda Roddy, of Florida Hospital Celebration Health, has sent a pastoral counseling assessment of how to help a patient with the spiritual and existential drama of this highly threatening case of cancer.
One of our purposes in initiating the Tumor Board feature was to form a body of case analyses that can be used in educating physicians about integrative approaches. We have recently taken the initiative and implemented this for the first time in my work with the University of Illinois at Chicago College of Medicine. In the Essentials of Clinical Medicine class for second-year students, a recent week's assignment was devoted to integrative cancer therapy. I presented an overview lecture to the entire class on integrative therapy of breast cancer, emphasizing relevant clinical studies as well as showing the type of approach used at my Evanston integrative cancer treatment center. The students were assigned the Integrative Tumor Board article by Brad Jacobs, dealing with a breast cancer patient, that Integrative Cancer Therapies published in 2003. 8 The article included contributions from nutrition, massage, traditional Chinese medicine, and conventional oncology. This article was used as the basis for small group discussions that were scheduled to follow the lecture. It usefully presented how a variety of different practitioners could contribute to the care of a patient, as well as acting as a primer on the basics of different integrative approaches.
The students have since reported that they found the discussion groups and reading interesting, productive, and clinically relevant and overall felt the integrative medicine assignment to be quite successful. We hope other medical educators will use the Tumor Board articles in this way. If you do use them, we'd love to hear from you on how these articles could better assist your students. We would also be interested in publishing any discussions and issues that arise out of this in the form of a Letter to the Editor. Our experience with students at UIC College of Medicine left us impressed by their insights into the relevance of this article format for all integrative and CAM practitioners.
